Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

Overview

Title: Comparison of different prophylaxis regimens for hemophilia A pediatric patients Principal Investigator: Assistant Professor Darintr Sosothikul, MD Research Question: Does different factor VIII dosage effect outcome of hemophilia treatment in term of breakthrough bleeding, number of hospital stay and day-off from school? Type Research: Clinical research Study design: Single center clinical trials Concise methodology: 1. Study Population: Children with hemophilia A who received treatment at KCMH from May 2015 to March 2016 will be enrolled in this study. The consent will be obtained before the study. 2. Observation and measurement: 1. History, interesting clinical data and laboratory data will be recorded in Clinical record Form (CRF) 2. Measurement: i. Complete blood count (CBC), Factor VIII level, Factor VIII inhibitor level ii. Number of breakthrough bleedings, number of hospital stay and day-off from school iii. Joint score from Hemophilia Joint Health Score 2.1 iv. EQ-5D-5L quality of life assessment score 3. Data analysis: The p-value of less than 0.05 will be considered statistically significant. Mann-Whitney test will be used to test correlation of these variables (CBC, Factor VIII level, Factor VIII inhibitor level, Number of breakthrough bleedings, number of hospital stay, day-off from school, Hemophilia Joint Health Score 2.1, EQ-5D-5L quality of life assessment score) Sample size: 16 patients Potential impacts: The outcomes of different factor VIII concentrate dose between 15-20 U/kg/dose 2 times/week and 35-40 U/kg/dose 1 time/week will be revealed. These outcomes include number of breakthrough bleeding, number of hospital stay, day-off from school, joint health and quality of life. The result of this study will guide further study on optimal dose and duration of factor VIII treatment of hemophilia A patients in the future.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2016

Interventions

  • Drug: FVIII
    • FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
  • Drug: FVIII
    • FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months

Arms, Groups and Cohorts

  • Experimental: Arm 1
    • FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
  • Experimental: Arm 2
    • FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months

Clinical Trial Outcome Measures

Primary Measures

  • Annualized bleeding rate per year
    • Time Frame: 10 months

Secondary Measures

  • Hemophilia joint health score
    • Time Frame: 10 months
  • Amount of FVIII use
    • Time Frame: 10 months
  • Quality of life score
    • Time Frame: 10 months
    • EQ-5D-5L (Thailand version)
  • Number of hospital stays
    • Time Frame: 10 months
  • Number of school days loss
    • Time Frame: 10 months

Participating in This Clinical Trial

Inclusion Criteria

  • Hemophilia patients with moderate (factor level 1-3%) or severe (factor level <1%) severity Exclusion Criteria:

  • Platelet count less than 100,000 /mm3 or other bleeding tendency – Hemophilia patients who have FVIII inhibitor >0.6 BU (modified Nijmogen method) – Hemophilia patients who have no bleeding symptoms

Gender Eligibility: All

Minimum Age: 6 Months

Maximum Age: 20 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chulalongkorn University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Darintr Sosothikul, Associate professor – Chulalongkorn University
  • Overall Official(s)
    • Darintr Sosothikul, MD, Principal Investigator, Chulalongkorn University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.